These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 34718071)

  • 1. New advances in pharmacoresistant epilepsy towards precise management-from prognosis to treatments.
    Xu C; Gong Y; Wang Y; Chen Z
    Pharmacol Ther; 2022 May; 233():108026. PubMed ID: 34718071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNAs in the development of resistance to antiseizure drugs and their potential as biomarkers in pharmacoresistant epilepsy.
    Bohosova J; Vajcner J; Jabandziev P; Oslejskova H; Slaby O; Aulicka S
    Epilepsia; 2021 Nov; 62(11):2573-2588. PubMed ID: 34486106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Search for New Screening Models of Pharmacoresistant Epilepsy: Is Induction of Acute Seizures in Epileptic Rodents a Suitable Approach?
    Löscher W
    Neurochem Res; 2017 Jul; 42(7):1926-1938. PubMed ID: 27502939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Possible interplay between the theories of pharmacoresistant epilepsy.
    Juvale IIA; Che Has AT
    Eur J Neurosci; 2021 Mar; 53(6):1998-2026. PubMed ID: 33306252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Outcomes of surgical treatment of patients with pharmacoresistant epilepsy].
    Krylov VV; Guekht AB; Trifonov IS; Lebedeva AV; Kaimovsky IL; Sinkin MV; Grigorieva EV; Grishkina MN; Shyshkina LV; Kochetkova OO
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(9. Vyp. 2):13-18. PubMed ID: 28005041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The current approach of the Epilepsy Therapy Screening Program contract site for identifying improved therapies for the treatment of pharmacoresistant seizures in epilepsy.
    Wilcox KS; West PJ; Metcalf CS
    Neuropharmacology; 2020 Apr; 166():107811. PubMed ID: 31790717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options.
    Löscher W; Potschka H; Sisodiya SM; Vezzani A
    Pharmacol Rev; 2020 Jul; 72(3):606-638. PubMed ID: 32540959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoresistant epilepsy: from pathogenesis to current and emerging therapies.
    Pati S; Alexopoulos AV
    Cleve Clin J Med; 2010 Jul; 77(7):457-67. PubMed ID: 20601619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic variations associated with pharmacoresistant epilepsy (Review).
    Cárdenas-Rodríguez N; Carmona-Aparicio L; Pérez-Lozano DL; Ortega-Cuellar D; Gómez-Manzo S; Ignacio-Mejía I
    Mol Med Rep; 2020 Apr; 21(4):1685-1701. PubMed ID: 32319641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Drug-resistant epilepsy].
    Nakken KO; Taubøll E
    Tidsskr Nor Laegeforen; 2009 Oct; 129(19):1986-9. PubMed ID: 19823202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid loss of efficacy to the antiseizure drugs lamotrigine and carbamazepine: a novel experimental model of pharmacoresistant epilepsy.
    Srivastava AK; Alex AB; Wilcox KS; White HS
    Epilepsia; 2013 Jul; 54(7):1186-94. PubMed ID: 23750799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of pharmacoresistant epilepsy.
    Berg AT
    Neurol Clin; 2009 Nov; 27(4):1003-1013. PubMed ID: 19853220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive factors for early identification of pharmacoresistant epilepsy.
    Sporis D; Basić S; Susak I; Colak Z; Marković I
    Acta Clin Croat; 2013 Mar; 52(1):11-5. PubMed ID: 23837267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of innovative therapeutics for pharmacoresistant epilepsy: challenges and needs.
    Weaver DF
    Epilepsia; 2013 May; 54 Suppl 2():56-9. PubMed ID: 23646972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent epileptiform discharges in the medial entorhinal cortex of kainate-treated rats are differentially sensitive to antiseizure drugs.
    West PJ; Saunders GW; Billingsley P; Smith MD; White HS; Metcalf CS; Wilcox KS
    Epilepsia; 2018 Nov; 59(11):2035-2048. PubMed ID: 30328622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Animal Models of Seizures and Epilepsy: Past, Present, and Future Role for the Discovery of Antiseizure Drugs.
    Löscher W
    Neurochem Res; 2017 Jul; 42(7):1873-1888. PubMed ID: 28290134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolving targets for anti-epileptic drug discovery.
    Raut D; Bhatt LK
    Eur J Pharmacol; 2020 Nov; 887():173582. PubMed ID: 32950499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoresistant epilepsy: unmet needs in solving the puzzle(s).
    Weaver DF; Pohlmann-Eden B
    Epilepsia; 2013 May; 54 Suppl 2():80-5. PubMed ID: 23646978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of a Preclinical Drug Screening Platform for Pharmacoresistant Epilepsy.
    Barker-Haliski ML; Johnson K; Billingsley P; Huff J; Handy LJ; Khaleel R; Lu Z; Mau MJ; Pruess TH; Rueda C; Saunders G; Underwood TK; Vanegas F; Smith MD; West PJ; Wilcox KS
    Neurochem Res; 2017 Jul; 42(7):1904-1918. PubMed ID: 28303498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lamotrigine-resistant corneal-kindled mice: A model of pharmacoresistant partial epilepsy for moderate-throughput drug discovery.
    Koneval Z; Knox KM; White HS; Barker-Haliski M
    Epilepsia; 2018 Jun; 59(6):1245-1256. PubMed ID: 29750337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.